Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial.
about
Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitorsImproved hemostasis in hemophilia mice by means of an engineered factor Va mutantPharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa.Key issues in inhibitor management in patients with haemophilia.Advances in the treatment of inherited coagulation disorders.Recombinant B domain deleted porcine factor VIII for the treatment of bleeding episodes in adults with acquired hemophilia A.A quantitative systems pharmacology model of blood coagulation network describes in vivo biomarker changes in non-bleeding subjects.Untangling the complexity of blood coagulation network: use of computational modelling in pharmacology and diagnostics.An activated factor VII variant with enhanced tissue factor-independent activity speeds wound healing in a mouse hemophilia B model.The endothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in vivo.Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin in healthy volunteers.Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors.Engineering a new generation of hemostatic agents: highlights of the Scientific Session on Hemostasis at the 2013 meeting of the American Society of Hematology.Predicting dosing advantages of factor VIIa variants with altered tissue factor-dependent and lipid-dependent activities.Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity.Development of a strategy and computational application to select candidate protein analogues with reduced HLA binding and immunogenicity.
P2860
Q24187069-BA08C69C-59F6-4F3A-9926-A443E1F77BE1Q34165592-C580D993-E0F4-491D-8863-CAFE307D2CBAQ34200694-2EA08E7B-A1CA-4532-9E93-A260AEF22DCDQ34548522-1E06C7F6-9350-4904-876B-B0E58A37BB6CQ37602415-02636850-C819-4F20-AA68-35E6353337B9Q38100271-74CB7220-B351-485D-A23B-11E688F00DF3Q38451206-4654EEF4-6D71-4360-98DC-E0695A6C591DQ38817825-C5D13396-C0FB-4BAA-B86F-8421AB29020FQ38990889-1FBE1C30-7C53-4F52-A34F-FED55479F7D5Q39940714-70AB4E7C-D24B-44D1-8472-7674F928C30DQ42791749-D62C434D-DB40-4AD1-BF9C-137196FB4FECQ45857094-D61D2FDA-5D6D-4077-8738-8F88B6F75A84Q45861084-A5A40EE9-F083-4E87-AF29-A47CE094B3DEQ45863501-8D3D06DD-7E3C-43F2-A11D-2BE3E7328918Q45865806-F591B401-E3BF-4513-A98D-AE9B64C151BDQ45879180-1D376C0F-AD92-462F-A679-AB8619B89BCEQ47716213-9E836BBE-94E8-48C3-BE8E-CBE1754F333E
P2860
Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Recombinant factor VIIa analog ...... a randomized controlled trial.
@en
Recombinant factor VIIa analog
@nl
type
label
Recombinant factor VIIa analog ...... a randomized controlled trial.
@en
Recombinant factor VIIa analog
@nl
prefLabel
Recombinant factor VIIa analog ...... a randomized controlled trial.
@en
Recombinant factor VIIa analog
@nl
P2093
P2860
P1476
Recombinant factor VIIa analog ...... a randomized controlled trial.
@en
P2093
1804 (adept(TM)1) Investigators
Ampaiwan Chuansumrit
Erich V de Paula
Jerzy Windyga
Johnny Mahlangu
Kaan Kavakli
László Nemes
Massimo Morfini
Midori Shima
Silke Ehrenforth
P2860
P356
10.1111/J.1538-7836.2011.04549.X
P577
2012-01-01T00:00:00Z